Express Mail Label No.: EV 871031056 US

Date of Deposit: July 27, 2007

Please type a plus sign (+) in this box



Page 1 of 1 Attorney Docket No.: 24492-010 NATL

PTO/SB (12-97) Approved for use through 9/30/00. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of equired to respond to a collection of information unless it displays a valid OMB control number.

	Form 144	19/PTO		Application Number	10/517,135					
				Filing Date of U.S. Nat'l Appl.	February 17, 2006					
	INFO	RMATION DISC	CLOSURE	First Named Inventor	Brand	Brand				
STATEMENT BY APPLICANT (use as many sheets as necessary)				Group Art Unit	1646	1646				
				Examiner Name	Gyan C	Gyan Chandra				
				Attorney Docket Number	24492-010 NATL					
				U.S. PATENT DOCUMENTS			The State of Control of Additional of Control of Contro			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate			
	*A1	5,624,895	04/29/97	Sobel	514	8				
	*A2	5,885,956	03/23/99	Nardi, et al.	514	2				
2 CONT. 200				FOREIGN PATENT DOCUMENTS						
Exam Initials				Name of Patentee(s) or Applicant(s)	Date of Publication		Translation Yes No			
Exam	Cite	P. Milder Company of Association Promises and Company of the Compa		ART - NON PATENT LITERATURE DOCUM			A design of the second of the			
Initials	No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. Carpenter, et al., "The Epidermal Growth Factor Family", Eds. Sporn and Roberts, Chapter 4:69-171 (1990)								
	C1		Fridkis-Hareli, et al., "Novel Synthetic Amino Acid Copolymers that Inhibit Autoantigen-Specific T Cell Responses and Suppress Experimental Autoimmune Encephalomyelitis", J. Clin. Invest., 109(12):1635-1643							
	C2	Fridkis-Hareli, Responses and								
	C2	Fridkis-Hareli, Responses and (2002)	Suppress Expension 1378: a CCK A	erimental Autoimmune Encephalomyelitis", J. Agonist with High Potency and Selectivity for	. Clin. Inve	st., 109(12):1635-1643			
		Fridkis-Hareli, Responses and (2002) Lin, et al., "A7 258(4 Pt 1):G6 Rooman, et al.,	Suppress Exp. 1378: a CCK A 48-G651 (199 "Gastrin Stim	erimental Autoimmune Encephalomyelitis", J. Agonist with High Potency and Selectivity for	CCK-A Re	st., 109(12 eceptors", A):1635-1643 Am. J. Physiol.,			
	C3	Fridkis-Hareli, Responses and (2002) Lin, et al., "A7 258(4 Pt 1):G6 Rooman, et al., from Normal E Sasaki, et al., "	Suppress Exp. 1378: a CCK A 48-G651 (199 "Gastrin Stim xocrine Pancre Dietary Docos	Agonist with High Potency and Selectivity for 0) ulates β-Cell Neogenesis and Increases Islet N	CCK-A Re	eceptors", A):1635-1643 Am. J. Physiol., rentiated but no			
	C3	Fridkis-Hareli, Responses and (2002) Lin, et al., "A7 258(4 Pt 1):G6 Rooman, et al., from Normal E Sasaki, et al., "Peripheral Bloc Selinfreund, et	Suppress Experiments and CCK A 48-G651 (199) "Gastrin Stim xocrine Pancre Dietary Docos and", J. Agric. I al., "Antisense	Agonist with High Potency and Selectivity for 0) ulates β-Cell Neogenesis and Increases Islet Neas Tissue", <i>Diabetes</i> , 51(3):686-690 (2002) ahexaenoic Acid Can Alter the Surface Expreser.	CCK-A Remarks From Sign of CD in Alterati	eceptors", A):1635-1643 Am. J. Physiol., rentiated but no 8 on T Cells in			
	C3 C4 C5	Fridkis-Hareli, Responses and (2002) Lin, et al., "A7 258(4 Pt 1):G6 Rooman, et al., from Normal E Sasaki, et al., "Peripheral Bloc Selinfreund, et Cytoskeletal Or Vergelli, et al.,	Suppress Experiments and Suppress Experiments Expe	Agonist with High Potency and Selectivity for 0) ulates β-Cell Neogenesis and Increases Islet Neas Tissue", Diabetes, 51(3):686-690 (2002) ahexaenoic Acid Can Alter the Surface Expressor Chem., 48(4):1047-1049 (2000).	CCK-A Remarks From State of CE as in Alteratic 2028 (1990)	eceptors", A):1635-1643 Am. J. Physiol., rentiated but no 8 on T Cells in 1 Morphology,			

* By the waiver of 37 CFR 1.98(a)(2)(ii) copies of the U.S. Patents A1-A2 are not submitted.

Examiner Signature	/Gyan Chandra/		Date Considered	/Gyan Chandra/
-----------------------	----------------	--	--------------------	----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.